Navidea Biopharmaceuticals IncOTC Pink - Limited Information:NAVB
- LAST PRICE0.0440
- TODAY'S CHANGE (%)0.0065 (17.3333%)
- Bid / Lots0.0375/ 280
- Ask / Lots0.0420/ 113
- Open / Previous Close0.0375 / 0.0375
- Day Range
- 52 Week Range
- Volume7,078
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NAVB |
|---|---|---|
| 09:32 ET | 6800 | 0.044 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Navidea Biopharmaceuticals Inc | 3.8M | -0.2x | --- |
Yield10 Bioscience Inc | 3.6M | -0.1x | --- |
Finch Therapeutics Group Inc | 3.7M | 0.0x | --- |
Biophytis SA | 3.5M | -0.1x | --- |
Virpax Pharmaceuticals Inc | 3.7M | -0.2x | --- |
Clearmind Medicine Inc | 3.8M | 0.0x | --- |
Company Information
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).
Contact Information
- Headquarters
- 4100 Horizons Drive, Suite 205COLUMBUS, OH, United States 43220
- Phone
- 614-793-7500
- Fax
- 614-793-7520
Executives
- Non-Executive Vice Chairman of the Board
- John Scott
- Chief Financial Officer, Principal Accounting Officer
- Craig Dais
- Director
- Joshua Wilson
- Independent Director
- Dana Moss
- Independent Director
- Jill Stefanelli
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.8M |
|---|---|
Revenue (TTM) | $610.00 |
Shares Outstanding | 100.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.12 |
EPS | $-0.21 |
Book Value | $-0.26 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 6,152.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,576,177.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
